|
Name |
3-Hydroxyvalproic acid
|
| Molecular Formula | C8H16O3 | |
| IUPAC Name* |
3-hydroxy-2-propylpentanoic acid
|
|
| SMILES |
CCCC(C(CC)O)C(=O)O
|
|
| InChI |
InChI=1S/C8H16O3/c1-3-5-6(8(10)11)7(9)4-2/h6-7,9H,3-5H2,1-2H3,(H,10,11)
|
|
| InChIKey |
LLPFTSMZBSRZDV-UHFFFAOYSA-N
|
|
| Synonyms |
3-Hydroxyvalproic acid; 58888-84-9; 3-Hydroxy-2-propylpentanoic acid; 3-Hydroxy Valproic Acid; 2-Propyl-3-hydroxypentanoic acid; 3-OH-VPA; 2-n-Propyl-3-hydroxypentanoic acid; 3-Hydroxy-valproic acid; CW51396YVP; 2-PROPYL-3-HYDROXYPENTANOICACID; Pentanoic acid, 3-hydroxy-2-propyl-; UNII-CW51396YVP; SCHEMBL1000793; 3-Hydroxy-2-propylpentanoicacid; CHEMBL3706502; CHEBI:80637; DTXSID10974384; LMFA01050494; AKOS006272875; 2-PROPYL-3-HYDROXYVALERIC ACID; FT-0670213; EN300-1296842; Q27149684
|
|
| CAS | 58888-84-9 | |
| PubChem CID | 134459 | |
| ChEMBL ID | CHEMBL3706502 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 160.21 | ALogp: | 1.5 |
| HBD: | 2 | HBA: | 3 |
| Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 57.5 | Aromatic Rings: | 0 |
| Heavy Atoms: | 11 | QED Weighted: | 0.644 |
| Caco-2 Permeability: | -4.671 | MDCK Permeability: | 0.00037356 |
| Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.014 |
| Human Intestinal Absorption (HIA): | 0.058 | 20% Bioavailability (F20%): | 0.003 |
| 30% Bioavailability (F30%): | 0.03 |
| Blood-Brain-Barrier Penetration (BBB): | 0.961 | Plasma Protein Binding (PPB): | 42.32% |
| Volume Distribution (VD): | 0.378 | Fu: | 44.49% |
| CYP1A2-inhibitor: | 0.027 | CYP1A2-substrate: | 0.315 |
| CYP2C19-inhibitor: | 0.021 | CYP2C19-substrate: | 0.591 |
| CYP2C9-inhibitor: | 0.004 | CYP2C9-substrate: | 0.894 |
| CYP2D6-inhibitor: | 0.009 | CYP2D6-substrate: | 0.211 |
| CYP3A4-inhibitor: | 0.007 | CYP3A4-substrate: | 0.039 |
| Clearance (CL): | 8.418 | Half-life (T1/2): | 0.847 |
| hERG Blockers: | 0.013 | Human Hepatotoxicity (H-HT): | 0.106 |
| Drug-inuced Liver Injury (DILI): | 0.053 | AMES Toxicity: | 0.007 |
| Rat Oral Acute Toxicity: | 0.096 | Maximum Recommended Daily Dose: | 0.016 |
| Skin Sensitization: | 0.089 | Carcinogencity: | 0.031 |
| Eye Corrosion: | 0.195 | Eye Irritation: | 0.914 |
| Respiratory Toxicity: | 0.195 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC000890 | ![]() |
0.514 | D0Y3KG | ![]() |
0.459 | ||
| ENC000306 | ![]() |
0.459 | D08QGD | ![]() |
0.313 | ||
| ENC001004 | ![]() |
0.421 | D03LGY | ![]() |
0.286 | ||
| ENC000550 | ![]() |
0.378 | D01OPV | ![]() |
0.275 | ||
| ENC000289 | ![]() |
0.364 | D00WUF | ![]() |
0.273 | ||
| ENC000874 | ![]() |
0.364 | D00ENY | ![]() |
0.262 | ||
| ENC000141 | ![]() |
0.351 | D02UDJ | ![]() |
0.250 | ||
| ENC001045 | ![]() |
0.350 | D07SJT | ![]() |
0.245 | ||
| ENC000824 | ![]() |
0.343 | D0EP8X | ![]() |
0.243 | ||
| ENC005934 | ![]() |
0.333 | D09PUL | ![]() |
0.242 | ||